In this episode, David Drapkin interviews drug developer, clinical psychiatrist, and Chief Medical Officer at HMNC Brain Health; Dr. Hans Eriksson. HMNC Brain Health is currently in Phase 2 trials for Ketabon, a ketamine-esque prolonged-release oral capsule which early studies show does not include any dissociation, and; as a lot of current medicine is guess work, they have also created a blood test (and are working on other predictive diagnostic tests) to identify specific common markers to show who will most likely respond to specific interventions. He discusses the stress response system and Vasopressin system; his thoughts on Compass Pathways’ phase 2 data; the famous Escitalopram vs. psilocybin study; how much of progress can be attributed to psychotherapy vs the compound itself; AI and machine learning; and how science is truly beginning to come to terms with the fact that all systems in the body are connected.

The post PT357 – Dr. Hans Eriksson – Precision Psychiatry, Ketabon, and The Stress Response System appeared first on Psychedelics Today.

Previous articlePsyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Next articleBexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board